|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SARAF |
Gene summary for SARAF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SARAF | Gene ID | 51669 |
| Gene name | store-operated calcium entry associated regulatory factor | |
| Gene Alias | FOAP-7 | |
| Cytomap | 8p12 | |
| Gene Type | protein-coding | GO ID | GO:0002115 | UniProtAcc | Q96BY9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51669 | SARAF | GSM4909285 | Human | Breast | IDC | 7.99e-04 | -2.15e-01 | 0.21 |
| 51669 | SARAF | GSM4909286 | Human | Breast | IDC | 3.45e-08 | -2.56e-01 | 0.1081 |
| 51669 | SARAF | GSM4909287 | Human | Breast | IDC | 4.84e-06 | -3.47e-01 | 0.2057 |
| 51669 | SARAF | GSM4909290 | Human | Breast | IDC | 8.38e-16 | -5.65e-01 | 0.2096 |
| 51669 | SARAF | GSM4909293 | Human | Breast | IDC | 1.69e-07 | -3.34e-01 | 0.1581 |
| 51669 | SARAF | GSM4909294 | Human | Breast | IDC | 4.67e-08 | -3.17e-01 | 0.2022 |
| 51669 | SARAF | GSM4909296 | Human | Breast | IDC | 1.74e-29 | -5.54e-01 | 0.1524 |
| 51669 | SARAF | GSM4909297 | Human | Breast | IDC | 2.13e-24 | -4.02e-01 | 0.1517 |
| 51669 | SARAF | GSM4909301 | Human | Breast | IDC | 1.66e-18 | -4.69e-01 | 0.1577 |
| 51669 | SARAF | GSM4909304 | Human | Breast | IDC | 3.07e-02 | -2.33e-01 | 0.1636 |
| 51669 | SARAF | GSM4909306 | Human | Breast | IDC | 2.16e-06 | -2.62e-01 | 0.1564 |
| 51669 | SARAF | GSM4909309 | Human | Breast | IDC | 4.88e-13 | -4.53e-01 | 0.0483 |
| 51669 | SARAF | GSM4909311 | Human | Breast | IDC | 2.16e-52 | -6.67e-01 | 0.1534 |
| 51669 | SARAF | GSM4909312 | Human | Breast | IDC | 2.71e-20 | -3.64e-01 | 0.1552 |
| 51669 | SARAF | GSM4909315 | Human | Breast | IDC | 4.69e-08 | -2.99e-01 | 0.21 |
| 51669 | SARAF | GSM4909316 | Human | Breast | IDC | 2.94e-03 | -3.87e-01 | 0.21 |
| 51669 | SARAF | GSM4909318 | Human | Breast | IDC | 2.51e-03 | -4.76e-01 | 0.2031 |
| 51669 | SARAF | GSM4909319 | Human | Breast | IDC | 2.85e-59 | -6.93e-01 | 0.1563 |
| 51669 | SARAF | GSM4909320 | Human | Breast | IDC | 9.37e-16 | -7.07e-01 | 0.1575 |
| 51669 | SARAF | GSM4909321 | Human | Breast | IDC | 2.14e-26 | -3.81e-01 | 0.1559 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
| GO:0051924 | Breast | IDC | regulation of calcium ion transport | 32/1434 | 255/18723 | 3.94e-03 | 3.22e-02 | 32 |
| GO:001095921 | Breast | DCIS | regulation of metal ion transport | 50/1390 | 406/18723 | 2.86e-04 | 4.22e-03 | 50 |
| GO:0010959 | Colorectum | FAP | regulation of metal ion transport | 83/2622 | 406/18723 | 2.06e-04 | 2.96e-03 | 83 |
| GO:00109597 | Endometrium | AEH | regulation of metal ion transport | 66/2100 | 406/18723 | 1.24e-03 | 1.07e-02 | 66 |
| GO:001095914 | Endometrium | EEC | regulation of metal ion transport | 70/2168 | 406/18723 | 4.12e-04 | 4.35e-03 | 70 |
| GO:00109598 | Oral cavity | NEOLP | regulation of metal ion transport | 59/2005 | 406/18723 | 9.36e-03 | 4.44e-02 | 59 |
| GO:00109594 | Stomach | GC | regulation of metal ion transport | 39/1159 | 406/18723 | 4.34e-03 | 3.58e-02 | 39 |
| GO:001095911 | Stomach | CAG with IM | regulation of metal ion transport | 36/1050 | 406/18723 | 4.52e-03 | 3.77e-02 | 36 |
| GO:00109592 | Stomach | CSG | regulation of metal ion transport | 36/1034 | 406/18723 | 3.54e-03 | 3.18e-02 | 36 |
| GO:00109593 | Stomach | CAG | regulation of metal ion transport | 23/552 | 406/18723 | 2.26e-03 | 2.50e-02 | 23 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SARAF | SNV | Missense_Mutation | c.781N>T | p.Pro261Ser | p.P261S | Q96BY9 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SARAF | insertion | Nonsense_Mutation | novel | c.416_417insGTTAGCCTA | p.Thr139_Glu140insLeuAlaTer | p.T139_E140insLA* | Q96BY9 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SARAF | insertion | Frame_Shift_Ins | novel | c.414_415insGCTAAGGAAAATAAATTGTGGTG | p.Thr139AlafsTer8 | p.T139Afs*8 | Q96BY9 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SARAF | SNV | Missense_Mutation | c.50N>A | p.Gly17Asp | p.G17D | Q96BY9 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SARAF | SNV | Missense_Mutation | novel | c.197N>T | p.Cys66Phe | p.C66F | Q96BY9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SARAF | SNV | Missense_Mutation | c.556G>A | p.Ala186Thr | p.A186T | Q96BY9 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SARAF | SNV | Missense_Mutation | novel | c.584G>T | p.Ser195Ile | p.S195I | Q96BY9 | protein_coding | deleterious(0) | possibly_damaging(0.876) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SARAF | SNV | Missense_Mutation | novel | c.167N>A | p.Arg56His | p.R56H | Q96BY9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| SARAF | SNV | Missense_Mutation | c.781N>A | p.Pro261Thr | p.P261T | Q96BY9 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SARAF | SNV | Missense_Mutation | novel | c.304G>T | p.Asp102Tyr | p.D102Y | Q96BY9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |